The U.S. Food and Drug Administration (FDA) has granted approval for Tivicay PD (dolutegravir) as a treatment option for HIV infection in newborns. This regulatory decision marks a significant advancement in the clinical management of pediatric HIV.

Tivicay PD, previously approved for other patient groups, now has an official indication supporting its use in neonates diagnosed with HIV. Healthcare professionals managing pediatric HIV patients should consider this newly approved therapy in their treatment protocols.

This approval is part of the FDA's ongoing commitment to enhance therapeutic options for vulnerable populations. The inclusion of Tivicay PD for newborns offers an additional resource to improve health outcomes in this critical patient demographic.